GLP-1s can be quite costly
"We are highly encouraged by the SYNCHRONIZE-1 topline results announced today by Boehringer Ingelheim, supporting the promise of survodutide as a differentiated therapy for people living with overweight or obesity and associated metabolic dysfunction," said David Kendall, MD, Chief Medical Officer of Zealand Pharma
Smartphone app could give voice to congestion in heart failure
Ideal for Active Lifestyles Formulated for athletes, fitness enthusiasts, and anyone pursuing a healthy, active lifestyle
Increasing evidence points to BBB dysfunction as an early biomarker of neurodegeneration, including AD (Montagne et al., 2015
The maximum FDA-studied and clinically used weekly dose of semaglutide is 2.4 mg, administered once per week via injection